1. Osteoporosis and osteopenia are not associated with T-cell activation in older cART-treated HIV-infected patients.
- Author
-
Krikke M, Klomberg RCW, van der Veer E, Tesselaar K, Verhaar HJJ, Hoepelman AIM, and Arends JE
- Subjects
- Absorptiometry, Photon, Age Factors, Aged, Bone Density, Bone Diseases, Metabolic epidemiology, Bone Diseases, Metabolic virology, HIV Infections complications, HIV Infections drug therapy, Humans, Lymphocyte Activation, Male, Middle Aged, Osteoporosis epidemiology, Osteoporosis virology, Pilot Projects, Prevalence, Risk Factors, T-Lymphocytes virology, Anti-HIV Agents therapeutic use, Bone Diseases, Metabolic immunology, HIV Infections immunology, Osteoporosis immunology, T-Lymphocytes immunology
- Abstract
Background: A higher risk of developing osteopenia/ osteoporosis has been seen in HIV-infected patients. We compared HIV-infected patients, all treated with combination antiretroviral therapy (cART), with a low bone mineral density (BMD) (T-score < -1) to those with a normal BMD (T-score > -1), examining the relation with T-cell activation and bone turnover markers (c-terminal telopeptide (CTX) and procollagen type 1 amino-terminal propeptide (P1NP))., Methods: In this single visit pilot study, bone turnover markers, T-cell activation (CD38 + HLA - DR +) and senescence (CD57+) of T cells were measured in patients who had previously undergone dual energy X-ray absorptiometry scanning., Results: All study participants (n = 16) were male, on cART, with a median age of 61 years (IQR 56-66). Nine patients had osteopenia/osteoporosis. When comparing the patients with osteopenia/osteoporosis with those with a normal BMD, no differences in activation and senescence were found. A relation was seen between higher bone formation (P1NP) and patients who were on cART for longer. The median length of cART use was 5.5 years (IQR 4.5-7.8), with all patients on nucleoside reverse transcriptase inhibitors, 88% on tenofovir, 63% on non-nucleoside reverse transcriptase inhibitors (NNRTIs) and 38% on protease inhibitors. Osteopenia/osteoporosis was seen in 100% of the patients on protease inhibitors versus 30% of those on NNRTIs., Conclusion: This study did not find an association between activated T cells and BMD, thus did not explain the higher prevalence of osteopenia/osteoporosis in HIV-infected patients. Interestingly, this small pilot showed that cART might influence BMD, with a possible negative effect for protease inhibitors and a possible protective effect for NNRTIs. These results warrant further investigation.
- Published
- 2017